Circulating let‐7 Predicts Hepatic Fibrogenesis of 12‐Month Post‐Nucleos(t)ide Analog Treatment in Patients With Hepatitis B Virus
ABSTRACT Chronic hepatitis B virus (HBV) infection is associated with potential complications of liver cirrhosis and hepatocellular carcinoma. To date, there are no effective and noninvasive clinical markers that can predict the risk of liver fibrosis early and accurately in chronic hepatitis B (CHB...
Saved in:
| Main Authors: | Yi‐Shan Tsai, Po‐Cheng Liang, Yi‐Hung Lin, Tyng‐Yuan Jang, Yu‐Ju Wei, Po‐Han Chen, Jia‐Ning Hsu, Meng‐Hsuan Hsieh, Ming‐Yen Hsieh, Chih‐Wen Wang, Zu‐Yau Lin, Ming‐Lun Yeh, Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang, Chia‐Yen Dai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Kaohsiung Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/kjm2.70015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
by: Rui Huang, et al.
Published: (2025-07-01) -
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyResearch in context
by: Rui Huang, et al.
Published: (2025-09-01) -
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
by: Jian Wang, et al.
Published: (2025-04-01) -
Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss
by: Na Gao, et al.
Published: (2025-03-01) -
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment
by: Jian Wang, et al.
Published: (2025-08-01)